ABSTRACT

Background: Gynecomastia (GM) is a benign proliferation of the glandular tissue of the breast in men. It is a frequent condition with a reported prevalence of 32–65%, depending on the age and the criteria used for definition. GM of infancy and puberty are common, benign conditions resolving spontaneously in the majority of cases. GM of adulthood is more prevalent among the elderly and proper investigation may reveal an underlying pathology in 45–50% of cases.

Objectives: The aim was to provide clinical practice guidelines for the evaluation and management of GM.

Materials and methods: A literature search of articles in English for the term ‘gynecomastia’ was conducted. Evidence-based recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.

Results: A set of five statements and fifteen clinical recommendations was formulated.

Conclusions: The purpose of GM assessment should be the detection of underlying pathological conditions, reversible causes (administration/abuse of aggravating substances), and the discrimination from other breast lumps, particularly breast cancer. Assessment should comprise a thorough medical history and physical examination of the breast and genitalia (including testicular ultrasound). A set of laboratory investigations may integrate the evaluation: testosterone (T), estradiol (E2), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicular stimulating hormone (FSH), thyroid stimulating hormone (TSH), prolactin, human chorionic gonadotropin (hCG), alpha-fetal protein (AFP), liver and renal function tests. Breast imaging may be used whenever the clinical examination is equivocal. In suspicious lesions, core needle biopsy should be sought directly instead. Watchful waiting is recommended after treatment of underlying pathology or discontinuation of substances associated with GM. T treatment should be offered to men with proven T deficiency. The use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and non-aromatizable androgens is not justified in general. Surgical treatment is the therapy of choice for patients with long-lasting GM.

SUMMARY OF STATEMENTS (S) AND RECOMMENDATIONS (R)

S1. Gynecomastia (GM) is a benign proliferation of glandular tissue of the breast in males.
S2. GM of infancy is a common condition that usually resolves spontaneously, typically within the first year of life.
S3. GM of puberty is a common condition, affecting approximately 50% of mid-pubertal boys; in more than 90% of cases, it resolves spontaneously within 24 months.
S4. The prevalence of GM in adulthood increases with increasing age; proper investigation may reveal an underlying pathology in approximately 45–50% of the cases.
S5. Male breast cancer is rare; GM should not be considered a premalignant condition.

The following recommendations are divided into ‘strong’, denoted by the number 1 and associated with the terminology...
We recommend’, and ‘weak’ denoted by the number 2 and associated with the phrase ‘we suggest’. The grading of the quality of evidence is denoted as follows: ⬤☺☺☺ for very low-quality evidence; ⬤☺☺☺ for low quality; ⬤☺☺☺ for moderate quality; and ⬤☺☺☺ for high quality.

**R1.** The presence of an underlying pathology should be considered in GM of adulthood. We recommend that the identification of an apparent reason for GM in adulthood, including the use of medication known to be associated with GM, should not preclude a detailed investigation (1 ⬤☺☺☺).

**R2.** We suggest that the initial screening to rule out lipomastia, obvious breast cancer, or testicular cancer might be performed by a general practitioner or another non-specialist (2 ⬤☺☺☺).

**R3.** We recommend that in those cases where a thorough diagnostic workup is warranted, it should be performed by a specialist (1 ⬤☺☺☺).

**R4.** We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, and administration or abuse of substances associated with GM (1 ⬤☺☺☺).

**R5.** We recommend that the physical examination should detect signs of under-virilization or systemic disease (1 ⬤☺☺☺).

**R6.** We recommend that breast examination should confirm the presence of palpable glandular tissue to discriminate GM from lipomastia (pseudo-gynecomastia) and rule out the suspicion of malignant breast tumor (1 ⬤☺☺☺).

**R7.** We recommend that the physical examination should include the examination of the genitalia to rule out the presence of a palpable testicular tumor and to detect testicular atrophy (1 ⬤☺☺☺).

**R8.** We recommend that genitalia examination is aided by a testicular ultrasound, as the detection of a testicular tumor by palpation has low sensitivity (1 ⬤☺☺☺).

**R9.** We suggest that a set of evaluations may include T, E₂, SHBG, LH, FSH, TSH, prolactin, hCG, AFP, and liver and renal function tests (2 ⬤☺☺☺).

**R10.** We suggest that breast imaging may offer assistance, where the clinical examination is equivocal (2 ⬤☺☺☺).

**R11.** We suggest that, if the clinical picture is suspicious for a malignant lesion, core needle biopsy should be performed (2 ⬤☺☺☺).

**R12.** We recommend watchdog waiting after treatment of underlying pathology or discontinuation of the administration/abuse of substances associated with GM (1 ⬤☺☺☺).

**R13.** We recommend that T treatment should be offered only to men with proven testosterone deficiency (1 ⬤☺☺☺).

**R14.** We do not recommend the use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or non-aromatizable androgens in the treatment of GM in general (1 ⬤☺☺☺).

**R15.** We suggest surgical treatment only for patients with long-lasting GM, which does not regress spontaneously or following medical therapy. The extent and type of surgery depend on the size of breast enlargement, and the amount of adipose tissue (2 ⬤☺☺☺).

**INTRODUCTION—DEFINITION**

Gynecomastia (GM) is a benign proliferation of glandular tissue of the breast in men. The term is derived from the Greek words ‘gynēka’ (woman) and ‘mastos’ (breast). GM can be unilateral or bilateral, most commonly the latter (Nuttall, 1979; Mieritz et al., 2017). GM has to be distinguished from pseudo-gynecomastia (i.e., lipomastia), which is characterized by excess fat deposition without glandular proliferation.

GM is a common condition with a prevalence that varies widely between 32 and 65%, depending on the age of the subjects studied and the criteria used for GM definition (Braunstein, 2007). GM shows three discrete peaks throughout a man’s lifespan: the first peak is observed during infancy, the second during puberty, and the third in middle-aged and elderly men (Nachti- gall, 1965; Knorr & Bidlingmaier, 1975; Nuttall, 1979). The purpose of the assessment of GM should be the detection of underlying pathological conditions and the discrimination from other breast lumps that mimic GM, particularly breast cancer.

In this guideline, we provide recommendations regarding the evaluation and management of GM based on the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system for grading both the quality of evidence and the strength of recommendations (Swiglo et al., 2008). According to this system, the strength of recommendation is divided into ‘strong’, denoted by the number 1 and associated with the terminology ‘we recommend’, and ‘weak’ denoted by the number 2 and associated with the phrase ‘we suggest’. The grading of the quality of evidence is denoted as follows: ⬤☺☺☺ for very low-quality evidence; ⬤☺☺☺ for low quality; ⬤☺☺☺ for moderate quality; and ⬤☺☺☺ for high quality (Swiglo et al., 2008).

**EPIDEMIOLOGY**

**Statements**

**S1.** Gynecomastia (GM) is a benign proliferation of glandular tissue of the breast in males.

**S2.** GM of infancy is a common condition that usually resolves spontaneously, typically within the first year of life.

**S3.** GM of puberty is a common condition, affecting approximately 50% of mid-pubertal boys; in more than 90% of cases, it resolves spontaneously within 24 months.

**S4.** Prevalence of GM in adulthood increases with increasing age; proper investigation may reveal an underlying pathology in approximately 45–50% of the cases.

**S6.** Male breast cancer is rare; GM should not be considered a premalignant condition.

**Evidence**

**Newborns and infants**

GM develops in 65–90% of all newborns as a possible consequence of the persistent action of estrogens, progesterone, and mammotrophic peptides that characterize the intrauterine milieu. It usually resolves spontaneously a few weeks after birth,
coinciding with the withdrawal of maternal hormones from the neonate’s circulation (Nachtigall, 1965). However, GM of the newborns may persist or even reappear in the first months of infancy, during the so-called ‘mini-puberty’ period, when a transient activation of the hypothalamic–pituitary–gonadal (HPG) axis occurs, causing an imbalance between estrogen and androgen concentrations (McKiernan & Hull, 1981; Madlon-Kay, 1986; Jayasinghe et al., 2010). GM of infancy is not associated with any sequels or aberrations of development; typically, it does not persist after the first year of life (Schmidt, 2002).

Adolescents
The prevalence of GM in adolescents varies from 22 to 69% (Nydick et al., 1961; Moore et al., 1984; Biro et al., 1990). The peak prevalence is observed during mid-puberty (Kumanov et al., 2007; Kilic et al., 2011; Mieritz et al., 2015), when the sex hormones surge, and growth and pubertal development are at the highest rate since the neonatal period (Tinggaard et al., 2012). Some pubertal boys experience intermittent GM (Mieritz et al., 2015). Underlying endocrinopathy cannot be detected in the vast majority of cases, and it has been stated that spontaneous regression can be expected within 6 months or less (Biro et al., 1990; Braunstein, 2007), but may persist up to 1–2 years (Lee et al., 1990; Nydick et al., 1961). The latter is in agreement with a recent longitudinal study, where the median duration of pubertal GM was 1.9 years (Mieritz et al., 2015) (Fig. 1) and thus longer than previously stated. In a cross-sectional study of 19-year-old Danish men from the general population, 2.8% were found to have persistent pubertal GM (Priskorn et al., 2018). Other studies have reported a frequency of 10%, however, in more selected populations (Nydick et al., 1961; Akgül et al., 2014; Mieritz et al., 2017).

Breast cancer
Male breast cancer is rare (lifetime risk of 0.1%) (Yu et al., 2015). Risk factors for breast cancer in men are Klinefelter syndrome (Brinton, 2011), a history of chest irradiation, and a family history of breast cancer (particularly mutations of the BRCA2 gene) (Biesma et al., 2015; Laitman et al., 2015). GM does not increase the risk of breast cancer (Volpe et al., 1999; Fentiman et al., 2006; Yu et al., 2015).

Figure 1 Gynecomastia of puberty: (A) at the age of 14 years and (B) at the age of 15.5 years. Spontaneous regression of breast enlargement is observed with associated progression of virilization (courtesy of Dr. G. Kanakis).
Values and preferences

Our statements stress the fact that GM is a common finding in infancy and puberty as a result of normal maturing processes and reflect our preference to avoid unnecessary testing of otherwise healthy boys. On the other hand, it is stated that GM of adulthood is associated with an underlying pathology in 50% of cases, warranting further evaluation.

PATHOPHYSIOLOGY

The exact mechanisms that lead to the development of GM are not entirely elucidated, but an increase in the estrogen-to-androgen balance is suggested to play an important role (Mathur & Braunstein, 1997; Narula & Carlson, 2014). Breast tissue contains receptors for both estrogens and androgens (Nichols et al., 1987; Sasano et al., 1996; Kanhai et al., 2000) (Fig. 2 adapted from Narula & Carlson, 2014). Estrogens stimulate proliferation, whereas androgens inhibit growth and differentiation of the mammary gland. Consequently, although the concentrations of circulating estrogens in adult men are similar to that of adult women in the early follicular phase, breast development in men does not occur. Overt androgen deficiency or estrogen excess may be detected, whereas occasionally the ratio between the hormones is abnormal, despite the presence of normal concentrations of both sex hormones, resulting in a relative androgen deficiency or a relative estrogen excess (Rochefort & Garcia, 1983). Furthermore, the activity of estrogen and androgen receptors might modify the hormonal signaling, leading to GM (Hellmann et al., 2012).

Diminished androgen action may be a result of primary or secondary T deficiency, but in rare cases may also be due to the insensitivity of the androgen receptor. The major part of androgens is converted to estrogens by the enzyme aromatase located in the gonads, adipose tissue, and breast tissue (Mathur & Braunstein, 1997). Aromatase activity is increased by luteinizing hormone (LH) stimulation, obesity, and alcohol, which are all common causes of GM (Ismail & Barth, 2001). Rare syndromes that alter enzymatic activity, such as aromatase excess syndrome, may also alter the estrogen-to-androgen balance either systematically (Stratakis et al., 1998) or locally, in the breast tissue (Sasano et al., 1996), leading to the development of GM.

Estrogen excess may follow increased production either from the gonads or the adrenal cortex, increased peripheral conversion of androgens to estrogens, or the administration of exogenous estrogens (Narula & Carlson, 2014). The negative feedback of estrogens on the secretion of LH from the pituitary gland further aggravates the derangement of the estrogen-to-androgen balance, which in turn leads to secondary T deficiency. Moreover, estrogens increase the sex hormone-binding globulin (SHBG) concentrations leading to even lower free T (fT) concentrations.

Conditions such as starvation and substantial weight loss have also been associated with GM as they may cause secondary T deficiency. As reproduction is considered an energy-consuming function, the body switches off the activity of the hypothalamic–pituitary–gonadal (HPG) axis in a generalized attempt to reduce energy expenditure, according to whether environmental circumstances are advantageous for reproduction or not (Jacobs, 1948; Smith et al., 1975; Sattin et al., 1984). By this mechanism, called ‘ontogenic regression’, all severe chronic diseases can potentially lead to the development of GM and may explain its extremely high prevalence in hospitalized or recovering men (Niewoehner & Nuttal, 1984).

CAUSES OF GYNECOMASTIA

Recommendations

R1. The presence of an underlying pathology should be considered in GM of adulthood. We recommend that the

Figure 2 The action of different hormones on breast tissue. Androgen receptor has an inhibitory effect on the development of breast cells, whereas other receptors have a stimulatory effect. A: androgen; AR: androgen receptor; E: estrogen; ER: estrogen receptor; Pg: progesterone; PgR: progesterone receptor; Prl: prolactin; IGF-1: insulin-like growth factor-1; IGF-1R: insulin-like growth factor-1 receptor. Reprinted by permission from: Springer Nature Customer Service Centre GmbH, Nat Rev Endocrinol, Gynaecomastia—pathophysiology, diagnosis and treatment. Narula & Carlson (2014).
identification of an apparent reason for GM in adulthood, including the use of medication known to be associated with GM, should not preclude a detailed investigation (1).エネルギー

Evidence
There are several pathological causes of GM (Table 1); some of them common, whereas others are very rare. Figure 3 (adapted from Mieritz et al., 2017) shows the distribution of causes detected in a clinical setting where men underwent a standardized workup (Mieritz et al., 2017). The probability of detecting an underlying cause of GM seems to increase with advanced age, and, in approximately 10% of patients, more than one cause may exist. Thus, the identification of one apparent reason for GM, such as the use of a medication, should not preclude a detailed investigation (Mieritz et al., 2017). In the proposed classification, various clinical entities are described and categorized according to the predominant endocrine derangement (e.g., low androgen concentrations), although they could fit into several.

Low androgen concentrations

Primary T deficiency
Primary testicular failure leads to low T production, which in turn evokes an elevation of LH output by the intact pituitary gland. The increased LH concentrations, though unable to completely ameliorate T deficiency, concomitantly enhance the activity of aromatase, resulting in an increased estrogen-to-androgen balance (Forest et al., 1979). Causes of primary T deficiency include Klinefelter syndrome, orchitis, trauma, testicular tumors, chemotherapy/radiotherapy, and rare causes, such as enzymatic defects of T production and cases of 46.XY DSD.

Secondary T deficiency
In such cases, the production of T decreases due to reduced secretion of gonadotropin-releasing hormone (GnRH), LH, or both resulting in a decrease of the inhibitory effect of androgens on the breast tissue. Causes for secondary T deficiency include isolated hypogonadotrophic hypogonadism (IHH) such as Kallmann’s syndrome, other genetic defects (e.g., PRO1 gene mutations), pituitary adenomas including hyperprolactinemia, and cranial irradiation. Opioid treatment or abuse can also lead to a centrally induced T deficiency (Gudin et al., 2015).

Hyperprolactinemia
Prolactin is not considered to cause GM per se; however, it does so by suppressing GnRH secretion at the level of the hypothalamus, leading to secondary hypogonadism. Nonetheless, prolactin receptors have also been found in male breast tissue, and may also contribute to the development of GM (Ferreira et al., 2008). Causes of hyperprolactinemia include pituitary adenomas, other lesions of the sellar region that cause destruction of the hypothalamic–pituitary dopaminergic pathway (the so-called ‘stalk effect’), decreased PRL clearance due to renal disease, or drug-induced hyperprolactinemia due to various medications, especially antipsychotic drugs (Krause, 2012; Grigg et al., 2017).

Renal disease
Both gonadal and hypothalamic/pituitary dysfunction can be induced by renal disease, resulting in T deficiency (Handelsman & Dong, 1993; Iglesias et al., 2012). Moreover, chronic renal failure is commonly associated with hyperprolactinemia, as a combined result of pituitary derangement, decreased renal clearance, and might be further aggravated by medications frequently used in renal disease (e.g., metoclopramide, methyl-dopa) (Hou et al., 1985).

Combination of high estrogen and androgen concentrations

Kennedy syndrome
This rare (1 in 40.000 men) syndrome is caused by an increased number of CAG (polyglutamine) repeats in the androgen receptor gene, which results in a lower sensitivity of the receptor (X-linked spinal and bulbar muscular atrophy) (La Spada et al., 1992). Although there is phenotypic variability, in the classical phenotype, clinical signs of mild androgen deficiency such as GM are combined with both high T and LH concentrations, implying partial to complete resistance to androgens. Neuromuscular problems (muscular weakness, atrophy, fasciculation) typically ensue after androgen resistance, at 40–50 years of age (Dejager et al., 2002).

Androgen insensitivity syndrome
In this rare syndrome (1 : 20.000 males), a genetic defect in the androgen receptor (more than 500 different mutations have been reported) leads to decreased sensitivity for T (Quigley et al., 1995; Gottlieb et al., 2012). In patients with complete androgen insensitivity syndrome (CAIS), the phenotype at birth is that of normal girls, whereas patients with partial androgen insensitivity syndrome (PAIS) display signs of under-virilization in varying degrees, hypospadias, undescented testes, or bifid scrotum at birth (Quigley et al., 1995). GM develops in the majority of patients during puberty and does not regress spontaneously (Hellmann et al., 2012; Paris et al., 2016).

Hyperthyroidism and hypothyroidism
GM has been reported in 40% or more of men with hyperthyroidism (Ashkar et al., 1970; Kidd et al., 1979). Increased thyroid...
hormone concentrations lead to increased production of SHBG, which in turn augments T binding. Consequently, LH secretion increases to maintain fT concentrations stable; this response, however, favors aromatization of androgens to estrogens, eventually disrupting estrogen-to-fT ratio (Forest et al., 1979).

Nonetheless, a direct stimulating effect of thyroid hormones on the activity of aromatase enzyme is also suggested (Kidd et al., 1979). GM has also been reported in the hypothyroid state. In this case, the relative mechanisms include reduced T concentrations, most likely due to an elevation of prolactin as a result of enhanced thyroid-releasing hormone (TRH) stimulation (Kraszas et al., 2010).

**Leydig and Sertoli cell tumors**

Leydig cell tumors are benign testicular tumors secreting excessive amounts of T and 17β-estradiol (E2). T is further aromatized in the adipose tissue into E2, which has lower affinity to SHBG compared to T, leading to an increased free E2/T ratio (Bercovici et al., 1981). To which degree Sertoli cell tumors are associated with the development of GM is questionable. Sertoli cell tumors typically emerge in syndromes such as Peutz–Jeghers and Carney complex (Kaltsas et al., 2000).

**Germ cell cancer**

Germ cell tumors (testicular or extra-testicular), particularly those that contain choriocarcinoma components, may lead to the development of GM. The choriocarcinoma components secrete human chorionic gonadotropin (hCG) that stimulates Leydig cells. This stimulation leads to both T production and increased aromatase activity resulting in a relatively increased E2 concentration (Forest et al., 1979).

**Abuse of anabolic androgenic steroids**

Use of anabolic androgenic steroid (AAS) is frequent in elite athletes, and in recreational sports and bodybuilding; lifetime prevalence of AAS abuse is 6.4% for men (Nieschlag & Vorona, 2015). When considering the effects of these drugs, it must be taken into consideration that they are often administered in very high and sometimes undefined doses, their purity might be unclear, and additional polypharmacy, including growth hormone, glucocorticoids, and hCG, is common. Moreover, 15% of nutritional supplements contain prohibited AAS, not declared on the supplement label (Geyer et al., 2014). Some androgens (e.g., T and androstenedione) are aromatized, while others [dihydrotestosterone (DHT) and many synthetic androgens] cannot undergo aromatization. GM is a very common adverse effect of AAS abuse, especially concerning androgens that aromatize (Nieschlag & Vorona, 2015; Christou et al., 2017). Moreover, most AAS regimens include hCG injections following high-dose AAS cycles to override HPG axis suppression and re-initiate T production. However, this may lead to or aggravate GM, due to an increased aromatase activity.

**High estrogen concentrations**

**Cannabis**

Cannabis abuse has been associated with GM in a few studies. The mechanism may include hyperprolactinemia and centrally induced hypogonadism (Mendelson et al., 1974; Olusi, 1980; Mieritz et al., 2017). An additional mechanism may be the similarity between the chemical structure of E2 and cannabinoids that is the major active component in marihuana (Harmon & Aliapoulios, 1972).

**Unintentional exposure to estrogens**

Occasionally, GM may emerge by the accidental ingestion of oral contraceptive pills. In adult men, unintended exposure to estrogen may occur during intercourse with women using estrogen replacement therapy by vaginal route (DiRaimondo et al., 1980). Environmental exposure to estrogen-like chemicals or phytoestrogens should also be considered (Henley et al., 2007). However, soy proteins, despite containing high concentrations of phytoestrogens, have not been proved to cause GM (Giampietro et al., 2004).
Obesity

Obesity is a condition associated with T deficiency of mainly secondary type (Matsumoto & Bremner, 2011; Boddi et al., 2014), whereas aromatization of androgens occurs mainly in the adipose tissue; consequently, obese men have an increased estrogen-to-androgen ratio (Mathur & Braunstein, 1997). Local excessive fat deposition in obese men may worsen the clinical appearance.

Liver disease

GM is commonly reported in patients with liver cirrhosis (Cava-naugh et al., 1990; Maruyama et al., 1991). Several mechanisms may be involved; increased SHBG concentrations resulting in lower fT increased hepatic aromatization of T to estrogens and use of medication for liver cirrhosis with anti-androgenic action (e.g., spironolactone) (Olivo et al., 1975; Maruyama et al., 1991).

Alcohol abuse

Chronic alcohol abuse has been associated with primary T deficiency and GM, independently of liver involvement; ethanol is proposed to be a ‘Leydig cell toxin’ (Castilla-García et al., 1987). The possible development of alcoholic liver disease further aggravates the clinical picture.

Other causes

Drug-induced GM

A broad spectrum of medications has been associated with GM. Generally, the documentation is sparse, and the reports use different definitions and methods to diagnose GM (Nuttall et al., 2015). Furthermore, it is often not clear if it is the disease per se, the ontogenic regression related to the disease, or an adverse effect of the given drug that causes GM. Some drugs incline a risk of GM, such as those that have estrogenic properties, enhance estrogen production, or impede biosynthesis, action, or metabolism of androgens (e.g., α-reductase inhibitors used for benign prostate hyperplasia or GnRH agonists for prostate cancer) (Table 2). For other medications, such as spironolactone, although the association with GM is strong, the mechanism is not clear (Chapman et al., 2007). A recent systematic review classified the medications that may cause GM in four categories by the level of evidence. A: proved causal role; B: highly probable role; and C: significant association could not be established (includes categories C and D of the original publication). Modified from: Krause (2012). ACE, angiotensin-converting enzyme; GH, growth hormone; HAART, highly active anti-retroviral therapy; hCG, human chorionic gonadotropin.

Table 2 Medications associated with gynecomastia

<table>
<thead>
<tr>
<th>Anti-androgens</th>
<th>Cardiovascular drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flutamide, bicalutamide</td>
<td>A Calcium channel blockers</td>
</tr>
<tr>
<td>Finasteride, dutasteride</td>
<td>A Amiodarone</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>A ACE inhibitors</td>
</tr>
<tr>
<td>Eplerenone</td>
<td>B Digoxin</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>B</td>
</tr>
<tr>
<td>Lavender oil</td>
<td>C Alcohol</td>
</tr>
<tr>
<td>Antibiotics</td>
<td></td>
</tr>
<tr>
<td>Isoniazid</td>
<td>C Amphetamines</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>C Heroin</td>
</tr>
<tr>
<td>Anti-uteri drugs</td>
<td>C Marijuana</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>C Methadone</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>B Hormones</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>B Estrogens, clomiphene citrate</td>
</tr>
<tr>
<td>Cancer chemotherapeutics</td>
<td>B hCG</td>
</tr>
<tr>
<td>Imatinib</td>
<td>C Anabolic steroids</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>C GH</td>
</tr>
<tr>
<td>Alkylating agents</td>
<td>C Other</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>A</td>
</tr>
<tr>
<td>Psychoactive drugs</td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>B Phenytin</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>C Penicillamine</td>
</tr>
<tr>
<td>Diazepam</td>
<td>C Theophylline</td>
</tr>
</tbody>
</table>

Causal role in GM by the level of evidence. A: proved causal role; B: highly probable role; and C: significant association could not be established (includes categories C and D of the original publication). Modified from: Krause (2012). ACE, angiotensin-converting enzyme; GH, growth hormone; HAART, highly active anti-retroviral therapy; hCG, human chorionic gonadotropin.

Androgen ablation therapy for prostate cancer

As prostate cancer is an androgen-dependent neoplasm, treatment strategies often involve medical castration (GnRH agonists), drugs that disrupt androgen production or action (anti-androgens), and occasionally bilateral orchiectomy. Therefore, GM is commonly observed among men treated for advanced prostate cancer (Alesini et al., 2013).

Values and preferences

The recommendation to exclude pathological entities associated with GM in adults, even in the presence of an apparent modifiable cause, places a high value on detecting life-threatening organic causes of GM, such as neoplasia.

CLINICAL EVALUATION

Recommendations

R2. We suggest that the initial screening to rule out lipomastia, obvious breast cancer, or testicular cancer might be performed by a general practitioner or another non-specialist (2 ⊕⊕⊕⊕).

R3. We recommend that in those cases where a thorough diagnostic workup is warranted, it should be performed by a specialist (1 ⊕⊕⊕⊕).

R4. We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, and administration or abuse of substances associated with GM (1 ⊕⊕⊕⊕).

Evidence

A suggested algorithm for the diagnostic approach of GM is presented in Fig. 4. A thorough diagnostic workup ought to be done only on those with adult-onset GM, provided that they are not in androgen ablation therapy (AAT) or are abusing AAS. AAT
or use of AAS does not exclude other underlying pathologies but make hormone profile evaluation virtually impossible (Nieschlag & Vorona, 2015). Exclusion of the presence of a testicular tumor may be sufficient.

The primary goal of the initial evaluation should be to confirm the presence of palpable glandular tissue and rule out the suspicion of malignant breast tumor or testicular tumor by palpation. It is essential to obtain a detailed medical history focusing on the onset and duration of GM as well as its previous occurrences. Persistence during adolescence or a new and rapidly developing condition may warrant further workup. Andrological history should include information on cryptorchidism, the onset of puberty, fertility status, and symptoms of T deficiency, including sexual functioning. Medications may lead to GM (Table 2). Thus, information on general illness, use of medications (both prescription and over-the-counter), use of AAS, alcohol, cannabis, and drug abuse (e.g., morphine and morphine-like substances) should also be noted (Braunstein, 2007).

Remarks

To which degree GM of puberty needs diagnostic workup is controversial; usually, it can be restricted to physical examination (Mieritz et al., 2017). The initial screening of GM might be performed by a general practitioner or another non-specialist (depending on the local health system) to rule out the obvious presence of mammary or testicular cancer, in which cases the patients need to be directly referred to mammary surgeons or urologists. The workup of GM should be carried out by a specialist.

Values and preferences

Our strategy emphasizes that initial evaluation of GM may be carried out by a general practitioner, adequately trained to distinguish the minority of cases that warrant further evaluation by a specialist.

Physical examination

Recommendations

R5. We recommend that the physical examination should detect signs of under-virilization or systemic disease (1 ⚫⚫⚫⚫).

Evidence

The physical examination includes anthropometric measurements (e.g., height, weight, body mass index, waist circumference, waist-to-hip ratio) to quantify obesity. Assessment of body proportions to document eunuchoidism (arm span, and upper and lower body segment measurement) might be relevant among younger patients. Signs of under-virilization (face and body hair pattern, loss of muscle mass) should also be described. The physical examination also includes palpation of the thyroid gland and identification of signs of hyperv- or hypothyroidism, hepatic or renal failure, and Cushing's disease.

Remarks

The general physical examination can suggest the underlying causes of GM. Frequently, more than one cause can contribute to the development of GM. Obesity, for example, is commonly associated with hypogonadism (Boddi et al., 2014), which can worsen an obesity-related pseudo-GM. Hence, the clinical suspicion should be confirmed with a specific diagnostic workup (see below).

Breast examination

Recommendations

We recommend that breast examination should confirm the presence of palpable glandular tissue to discriminate GM from lipomastia (pseudo-gynecomastia) and rule out the suspicion of malignant breast tumor (1 ⚫⚫⚫⚫). In obese males, it may occasionally be difficult to distinguish between glandular and fat tissue (pseudo-GM). Glandular tissue is often bilateral and felt like a soft, elastic, or firm mass of tissue, sometimes tender, and in the majority of cases concentrically located behind the areola (Braunstein, 2007). In men who have had GM for more than 2–3 years, the presence of fibrosis that has developed may make it difficult to detect the presence of true GM. During puberty, GM is often associated with tenderness of the breast tissue.

Genital examination

Recommendations

R7. We recommend that the physical examination should include the examination of the genitilia to rule out the presence of a palpable testicular tumor and to detect testicular atrophy (1 ⚫⚫⚫⚫).

R8. We recommend that genitalia examination is aided by a testicular ultrasound, as the detection of a testicular tumor by palpation has low sensitivity (1 ⚫⚫⚫⚫).
Figure 4 Clinical and biochemical workup of adult men presenting with breast development. AAS: anabolic androgenic steroid; ALP: alkaline phosphatase; ALT: alanine aminotransferase; E₂: estradiol; IGF-1: insulin-like growth factor-1, LH: luteinizing hormone; SHBG: sex hormone-binding globulin; T: testosterone; T₃: triiodothyronine; T₄: thyroxine; TSH: thyroid-stimulating hormone. Reprinted by permission from: Bioscientifica Limited, European journal of Endocrinology, Gynaecomastia in 786 adult men: clinical and biochemical findings, Mieritz et al. (2017) (modified).
Table 3 Suggestions for the diagnostic approach of men with gynecomastia

<table>
<thead>
<tr>
<th>Medical history collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Duration of gynecomastia, uni- or bilateral location, tenderness</td>
</tr>
<tr>
<td>- Previous occurrences of gynecomastia</td>
</tr>
<tr>
<td>- Previous or current cryptorchidism, fertility status</td>
</tr>
<tr>
<td>- Symptoms of testosterone deficiency, hyperthyroidism, or systemic illnesses</td>
</tr>
<tr>
<td>- Complete list of medication, use of recreational drugs and/or supplements</td>
</tr>
</tbody>
</table>

| Physical examination                                                                       |
| - Uni- or bilateral location, size, tenderness                                            |
| - Height, weight, and body mass index                                                     |
| - Thyroid palpation                                                                        |
| - General (signs of systemic illnesses) and genital (testicular size, consistency) physical examination |

First-level laboratory blood tests and instrumental investigations

| - LH, FSH, T, E2, SHBG                                                                      |
| - β-hCG                                                                                   |
| - TSH                                                                                     |
| - Prolactin                                                                               |
| - Liver function: SGOT, SGPT, albumin                                                     |
| - Renal function: creatinine, urea                                                        |
| - Testicular ultrasound scan                                                               |

Additional laboratory blood investigations

| - DHEA-S, Δ4-Δ                                                  |
| - Karyotype                                                  |
| - DNA for genetic analysis, such as PCR for androgen receptor |

Δ4-Δ, Δ4-androstenedione; DHEA-S, dehydroepiandrosterone-sulfate; E2, 17β-estradiol; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone; PCR, polymerase chain reaction; SHBG, sex hormone-binding globulin; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate-pyruvate transaminase; T, testosterone; TSH, thyroid-stimulating hormone. *Needed when the basic investigation has not revealed the cause of the GM.

Evidence

The basic hormonal evaluation includes T, E2, SHBG, LH, FSH, TSH, prolactin, and tumor markers of testicular or extragonadal cancer (hCG and AFP). If Cushing’s disease, hepatic or renal failure is suspected, the appropriate laboratory tests should be performed.

Increased gonadotropin concentrations combined with low T concentrations are suggestive of primary T deficiency. High LH concentrations in the presence of normal T (compensated T deficiency, Fig. 7) may also cause GM due to the aromatase-stimulating effect of LH (Forest et al., 1979). In cases of testicular or ectopic hCG production, T concentrations are usually high-normal and LH and FSH concentrations suppressed.

Remarks

Low total T concentrations are not always indicative of T deficiency due to changes in SHBG concentrations. Thus, measurement of SHBG in addition to total T and, in equivocal cases, assessment of fT should be carried out (Wu et al., 2010). The current immunoassays of fT and E2 in the males still lack the desired accuracy, and results should be interpreted with caution (Morales et al., 2012; Handelsman et al., 2014). Preferably, fT should be either measured directly by assays including equilibrium dialysis or, alternatively, calculated indirectly by one of the available accurate formulas (Bhasin et al., 2018). Regarding E2 measurement, liquid chromatography–tandem mass spectrometry (LC-MS/MS) is more accurate and should be preferred over currently available immunoassays (Huhtaniemi et al., 2012). Furthermore, it may occasionally be insufficient to conclude about hormonal disturbances based on whether individual hormones are within the reference range. As an example, E2 might be high normal and T low normal, but the E2-T ratio increased. Reference levels are population-based, and there are no clear biological thresholds; subtle but relevant changes may be overlooked if the evaluation of hormone levels is merely performed rather than breast imaging (2 R10). We suggest that breast imaging may offer assistance, where the clinical examination is equivocal (2 R11). We suggest that, if the clinical picture is suspicious for a malignant lesion, core needle biopsy should be performed rather than breast imaging (2 R11).

Breast imaging

Evidence

In the vast majority of cases, the clinical picture of GM is informative, and there is no need to perform imaging (Chau et al., 2016). However, imaging may offer valuable assistance in case of obese men where breast examination and distinction from lipomastia can be difficult or in cases with fibrosis/hyalinization. Mammography has been shown to be the most sensitive and...
ultrasound, the most specific technique for the detection of malignancy, whereas ultrasound is more convenient (Muñoz Carrasco et al., 2010).

Remarks
If the clinical picture is suspicious of a malignant lesion, the diagnostic approach should opt directly to perform a core needle biopsy (Hines et al., 2007).

Values and preferences
Our recommendations on hormonal evaluation place a high value on identifying those men who present GM in the setting of an overt endocrinological disorder, whereas the recommendations on breast imaging place a high value on avoiding unnecessary imaging studies that may delay the acquisition of a histological diagnosis in a suspicious lesion.

MANAGEMENT
Any underlying pathology should be treated, if possible (e.g., T substitution in case of T deficiency, and treatment of hyperthyroidism or hyperprolactinemia). T treatment is effective only in patients with proven T deficiency, as in eugonadal men it may worsen GM due to enhanced aromatization to E₂ (Forest et al., 1979; Wu et al., 1996). If a pharmaceutical substance is suspected to be the cause, the medication should be changed or discontinued, if possible. In the case of AAS abuse, cessation of the substance should be encouraged.

Watchful waiting

Recommendations
R12. We recommend watchful waiting after treatment of underlying pathology or discontinuation of the administration/abuse of substances associated with GM (1 ⊗⊗⊗⊗).

Evidence
In cases of GM of puberty or GM of adulthood with negative physical and hormonal investigations, there is a fair chance that
the condition will disappear spontaneously, especially if it is of recent onset (Nydict et al., 1961; Lee, 1975; Biro et al., 1990; Mieritz et al., 2017).

**Remarks**

Particular attention should be paid to GM in boys of prepuberal age, a rare finding, which is not anticipated by normal hormone fluctuations and warrants thorough evaluation to rule out an underlying pathology (Einav-Bachar et al., 2004).

**Medical treatment**

**Recommendations**

R13. We recommend that T treatment should be offered only to men with proven testosterone deficiency (1 ⊕⊕⊕).  
R14. We do not recommend the use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or non-aromatizable androgens in the treatment of GM in general. (1 ⊕⊕○).

**Evidence**

In cases of overt T deficiency, T replacement has been reported to ameliorate GM (Dobs et al., 1999); however, this is not the case in eugonadal men, where it is reported to aggravate or even produce GM due to aromatization of excessive T to E2 (Wu et al., 1996). Percutaneous treatment with non-aromatizable androgens, such as DHT, has also been reported to be effective in small series of patients (Kuhn et al., 1983; Eberle et al., 1986; Benveniste et al., 2001).

SERMs, such as tamoxifen, raloxifene, and clomiphene citrate or AIs, have been tested in the treatment of idiopathic GM, considering the inhibitory action they exert on breast tissue (Lawrence et al., 2004).

Tamoxifen is the best-studied SERM. It has been used in GM of puberty with partial response in the vast majority of boys (90%) but a complete response in <10% (Derman et al., 2003). Similarly, in adults with GM, a reduction in tenderness and breast size has been reported with tamoxifen, but no patient experienced complete remission (Khan et al., 2004; James et al., 2012). If no pathology has been shown and pain remains a problem, further diagnostic procedures ought to be undertaken, and alternative diagnoses (e.g., hematoma or infections) should be ruled out rather than treating with SERMs.

In the rare cases of increased aromatase activity per se, which can be identified by the presence of elevated estrogen concentrations, treatment with AIs may be considered as an alternative to surgical treatment (Braunstein, 1999). Nevertheless, evidence regarding their efficacy is low, and the long-term adverse effects of AIs on bone metabolism have to be considered (Plourde et al., 2004; Riepe et al., 2004; Mauras et al., 2009).

**Remarks**

Limited information from randomized controlled trials (RCTs) is available for the use of SERMs and DHT in the treatment of idiopathic GM. DHT has not been tested in RCTs. The only RCT including SERMs in the treatment of GM did not prove any benefit (McDermott et al., 1990). In accordance with these results, the use of SERMs is not justified for the treatment of GM with the possible exception of tamoxifen in cases of painful GM of recent onset as it offers rapid relief from pain, regardless of the magnitude of response. In contrary, there is a substantial body of evidence that supports the use of SERMs or AIs for the prevention of GM in patients with prostate cancer undergoing AAT (Boccardo et al., 2005; Dobs & Darkes, 2005). An alternative modality is low-dose prophylactic radiotherapy (PRT) (Dicker, 2003), which, although less effective, is more practical, as few short-term applications are required.

Regarding safety issues, PRT has been associated with local skin rash/irritation and asthenia whereas SERMs (tamoxifen in particular) with constipation/diarrhea and pruritus. All these adverse effects are of mild degree and resolve spontaneously. No long-term sequel (e.g., secondary malignancy, relapse of prostate cancer) has been documented for either therapy (Perdonà et al., 2005).

**Surgical treatment**

**Recommendations**

R15. We suggest surgical treatment only for patients with long-lasting GM, which does not regress spontaneously or following medical therapy. The extent and type of surgery depend on the size of breast enlargement, and the amount of adipose tissue (2 ⊕⊕⊕○).

**Evidence**

Only a small proportion of patients with GM will need surgical treatment. The vast majority of patients either will experience...
spontaneous regression or will receive specific treatment that will relieve the underlying pathology. The classical surgical approach is the nipple-sparing subcutaneous mastectomy (Lettman & Schurter, 1976; Webster, 1980). However, suction lipectomy has proved helpful for tapering the edges, and it may be used as the sole procedure, in mild GM (Sarkar et al., 2014). It is essential to preserve a button of tissue under the areola to maintain a sufficient blood supply and to prevent the nipple from retracting (Boljanovic et al., 2003). In severe GM, skin resection is often necessary in combination with transposition of the nipple-areola complex. The most frequent surgical complications are numbness of the nipple and adherence of the areola to the pectoral muscle (Rahmani et al., 2011).

Remarks
Any surgical treatment should not be offered until after an observation period has been allowed. Clinical practice may vary according to local algorithms and legislation (e.g., in Denmark, surgical treatment of adult-onset GM will usually not be offered in public hospitals unless the GM has lasted for at least one year after treatment of the underlying pathology or has lasted at least one year without the detection of any pathology). In the case of pubertal GM, the observation period may be extended up to two years of persistence, until surgery is recommended (Bannayan & Hajdu, 1972; Mietz et al., 2017).

Persistent GM may have significant psychosocial and psychological consequences. Available literature suggests the association of GM with depression, anxiety, low self-esteem and body image concerns, issues that may lead patients to maladaptive coping mechanisms such as wrapping of the chest, walking with slumped shoulders and arms crossed, and eventually restriction of physical and social activities (Ordaz & Thompson, 2015). It should be noted though that most of the relevant data refer to adolescents, with other populations being less represented (Kinsella et al., 2012). In such cases of GM where the disease causes considerable cosmetic and psychological distress, surgical treatment is justified (Mathur & Braunstein, 1997; Kasielska & Antoszewski, 2011; Rew et al., 2015). Older studies suggest better psychological post-operative adjustment when surgery is combined with psychotherapy (Schonfeld, 1962); however, recent data are missing.

Values and preferences
Our recommendations on medical management of GM reflect our preference to avoid empirical therapies that lack a substantial body of evidence. Instead, we promote watchful waiting after the withdrawal of detrimental factors and/or the correction of underlying pathologies and place a high value on conserving T replacement therapy for those with unequivocally confirmed T deficiency. Our recommendation on surgical treatment stresses that this is the therapy of choice in the presence of persistent pubertal GM, especially when associated with significant psychological distress or when the correction of the predisposing factor does not result in remission of GM after a sufficient period of surveillance (usually more than one year).

CONCLUSIONS
GM is a common condition associated with benign hormonal processes of maturation of the male adolescent in the majority of cases. On the other hand, GM of the elderly is more often associated with underlying pathological conditions. The assessment of GM should aim the detection of such conditions or the administration/abuse of aggravating substances as well as the exclusion of the very rare male breast cancer. The cornerstone of evaluation are thorough medical history and physical examination including the breast and genitalia (supported by testicular ultrasound). Laboratory investigations may reveal underlying systematic disorders, whereas the role of breast imaging is still debated: Core needle biopsy should be sought in any clinical suspicious breast lesion. Watchful waiting and reassurance are reasonable options after underlying pathology, or the administration/abuse of substances associated with GM has been excluded or treated. The use of medical regimens, including SERMS, AIs, or DHT, still lacks substantial evidence to recommend their generalized use, while surgical treatment remains the therapy of choice for patients with long-lasting GM.

REFERENCES


